NAA Services for Anti-PRDX2/3 Antibody

Natural autoantibodies (NAA) have shown wide associations with a variety of human diseases and have been served as effective biomarkers for diseases diagnosis and therapeutic monitoring. With abundant experience and high-end technologies, Creative Biolabs has developed a series of innovative and diversified NAA platforms to detect and analyze NAA associated disease indicators. Anti-PRDX2/3 is one of the autoantibodies serving as potential biomarkers for the screening and diagnosis of nasopharyngeal carcinoma (NPC). Now, we are proud to offer fast and convenient NAA services for our worldwide customers to help them get a milestone success in the NAA projects.

Background of PRDX2/3

PRDX2/3, the abbreviation of peroxiredoxin-2/3, belongs to the peroxiredoxin (PRDX) family of peroxidases. It is abundantly expressed in cells and metabolizes intracellular H2O2 through the thioredoxin system to reduce hydrogen peroxide and alkyl hydroperoxides. In addition, PRDX2/3 may play an antioxidant protective role in cells and may contribute to the antiviral activity of CD8(+) T-cells. Recently, PRDX2/3 has been shown to induce autoantibody responses in patients with NPC. Because of this correlation, PRDX2/3 autoantigen may be a valid indicator of NPC, an effective target for some experimental engineered T-cell therapies and a possible target for cancer vaccine or immunotherapy. PRDX2/3 may also have a proliferative effect and play a role in cancer development or progression.

The Role of Anti-PRDX2/3 Antibody in Nasopharyngeal Carcinoma

NPC is a major head and neck cancer with high occurrence in Southern China and Southeast Asia. Data shows that the overall survival in early-stage NPC patients is obviously longer than that with advanced stage. Unfortunately, 75-90% of patients with NPC present with late stage of disease at clinical diagnosis because of its deep location and vague symptoms. Therefore, a screening and early detection of indicators for the early diagnosis of NPC may significantly contribute to improving NPC therapy and prognosis.

Besides the traditional EBV viral capsid antigen immunoglobulin A (VCA-IgA) and EBV DNA, there are some other most commonly used serum/plasma biomarkers for NPC, such as anti-PRDX2/3 autoantibodies, which have been shown to abundantly present in serum samples from NPC patients. So, it has been suggested as an ideal biomarker and immunological hallmark of NPC with superior diagnostic accuracy. Tumor growth and differentiation, cTNM stage and abdominal pain are demonstrated to be related to anti-PRDX2/3 autoantibodies. Therefore, autoantibodies against PRDX2/3 serving as supplementary biomarkers for the screening and early diagnosis of NPC could be detected prior to the onset of cancer.

Fig.1 Anti-PRDX2 and PRDX3 autoantibodies levels in normal and NPC sera. (Lin, et al., 2017)Fig.1 Levels of autoantibodies against PRDX2 and PRDX3 from NPC sera and normal sera.1

Anti-PRDX2/3 Autoantibody Detection

At Creative Biolabs, we can provide a whole set of services for the detection of anti-PRDX2/3 autoantibodies. Based on years of extensive experience in NAA research, we are able to detect and analyze anti-PRDX2/3 autoantibodies with different and suitable methods, including but not limited to autoantigen/autoantibody array, peptide array, Enzyme-Linked Immunosorbent Assay (ELISA), LIPS, WB and dot blot.

What Can We Do?

Aided by our well-established platforms and experienced scientists, we can provide a comprehensive range of NAA services, from NAA detection, NAA profiling, to NAA epitope mapping. In addition, a wide spectrum of NAA products is also available for your choice.

Features of Our Services

The identification and detection of predictive/prognostic anti-PRDX2/3 autoantibodies are of great clinical importance to the improvement of the curative rate and survival rate of NPC patients. Creative Biolabs is well-positioned to deliver the largest portfolio of products and services about NAA. Our proven and optimized platforms can help you quickly get satisfactory results without repeated trials. We also provide custom services based on the requirements of the clients to meet their specific demand. Please contact us for more information.

Reference

  1. Lin, Lie-Hao, et al. "Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma." Clinical proteomics 14.1 (2017): 1-10.
For Research Use Only | Not For Clinical Use

Related Services:

Products:

Resource:

Applications:

Online Inquiry
Inquiry